Cargando…
Rapamycin Antagonizes BCRP-Mediated Drug Resistance Through the PI3K/Akt/mTOR Signaling Pathway in mPRα-Positive Breast Cancer
PURPOSE: Overexpression of breast cancer (BCa) resistance protein (BCRP) is detected in approximately 30% of BCa cases. BCRP indicates a poor response to chemotherapy, and it has become a classic target to overcome drug-resistant tumor cells. In this study, we aimed to explore the mechanism of BCRP...
Autores principales: | Zhang, Jing, Hu, Jing, Li, Weiwei, Zhang, Chunyan, Su, Peng, Wang, Yan, Sun, Wei, Wang, Xiao, Li, Li, Wu, Xiaojuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071953/ https://www.ncbi.nlm.nih.gov/pubmed/33912444 http://dx.doi.org/10.3389/fonc.2021.608570 |
Ejemplares similares
-
Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017) -
Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
por: Murray, James T., et al.
Publicado: (2018) -
Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
por: Artoni, Filippo, et al.
Publicado: (2023) -
Expression and Purification of Human Membrane Progestin Receptor α (mPRα)
por: Hossain, Md. Babul, et al.
Publicado: (2015) -
mPR-Specific Actions Influence Maintenance of the Blood–Brain Barrier (BBB)
por: Abou-Fadel, Johnathan, et al.
Publicado: (2022)